E-drug: PA824, new TB drug (cont)
---------------------------------------------
Dear Mrs Tanguy,
If I read the announcement correctly, the Chiron/TBA deal is that TBA will
finance the development of PA824, and that if the drug proves valuable,
Chiron will have a de facto monopoly on its marketing in richer countries.
It is not clear whether countries like Brazil or South Africa would fall
into Chiron's definition of richer countries or not.
In my opinion, the only way to decide whether this deal is a good one or
not, is to know the extent of development to which PA824 has already been
taken by Chiron (pre-clinical, phase I, phase II ?).
If this is all about Chiron getting the public to pay for developing a
pseudo-orphan drug in exchange for impoverished-country marketing rights...
then maybe the new goods is only that the North is at last researching
impoverished-country diseases, and not that Chiron has lent itself to a
supergreat partnership with TBA.
Khalil Elouardighi
ACT UP-Paris
Khalil Elouardighi <gerrold@wanadoo.fr>
--
To send a message to E-Drug, write to: e-drug@usa.healthnet.org
To subscribe or unsubscribe, write to: majordomo@usa.healthnet.org
in the body of the message type: subscribe e-drug OR unsubscribe e-drug
To contact a person, send a message to: owner-e-drug@usa.healthnet.org
Information and archives: http://www.healthnet.org/programs/edrug.html